about
Next generation sequencing in endocrine practiceContinuous Glucose Monitoring Enables the Detection of Losses in Infusion Set Actuation (LISAs).Successful Application of Closed-Loop Artificial Pancreas Therapy After Islet Autotransplantation.Duration of Infusion Set Survival in Lipohypertrophy Versus Nonlipohypertrophied Tissue in Patients with Type 1 Diabetes.Growth hormone treatment of patients with Fanconi anemia after hematopoietic cell transplantationOutpatient Closed-Loop Control with Unannounced Moderate Exercise in Adolescents Using Zone Model Predictive Control.Ambulatory glucose profile analysis of the juvenile diabetes research foundation continuous glucose monitoring dataset-Applications to the pediatric diabetes population.Sporadic Insulinoma Presenting as Early Morning Night Terrors.Obesity in children with congenital adrenal hyperplasia in the Minnesota cohort: importance of adjusting body mass index for height-age.Practical Considerations on the Use of Continuous Glucose Monitoring in Pediatrics and Older Adults and Nonadjunctive Use.Refining the closed loop in the data age: research-to-practice transitions in diabetes technology.Closed-Loop Control Without Meal Announcement in Type 1 Diabetes.Closed-Loop Control During Intense Prolonged Outdoor Exercise in Adolescents With Type 1 Diabetes: The Artificial Pancreas Ski Study.The dawn of automated insulin delivery: A new clinical framework to conceptualize insulin administration.Predictive hyperglycemia and hypoglycemia minimization: In-home double-blind randomized controlled evaluation in children and young adolescents.Optimizing Hybrid Closed-Loop Therapy in Adolescents and Emerging Adults Using the MiniMed 670G System.Safety and Feasibility of the OmniPod Hybrid Closed-Loop System in Adult, Adolescent, and Pediatric Patients with Type 1 Diabetes Using a Personalized Model Predictive Control Algorithm.Progress in Diabetes Technology: Developments in Insulin Pumps, Continuous Glucose Monitors, and Progress towards the Artificial Pancreas.Fully Closed-Loop Multiple Model Probabilistic Predictive Controller Artificial Pancreas Performance in Adolescents and Adults in a Supervised Hotel Setting.Insulin Infusion Sets and Continuous Glucose Monitoring Sensors: Where the Artificial Pancreas Meets the Patient.Relevance of Bolus Calculators in Current Hybrid Closed Loop Systems.Artificial Pancreas in Young Children.Predictive Low-Glucose Suspend Reduces Hypoglycemia in Adults, Adolescents, and Children With Type 1 Diabetes in an At-Home Randomized Crossover Study: Results of the PROLOG TrialMalglycemia is associated with poor outcomes in pediatric and adolescent hematopoietic stem cell transplant patientsAnkyloglossia, exclusive breastfeeding, and failure to thriveOngoing Debate About Models for Artificial Pancreas Systems and In Silico StudiesPreserving Skin Integrity with Chronic Device Use in DiabetesMiniMed 670G hybrid closed loop artificial pancreas system for the treatment of type 1 diabetes mellitus: overview of its safety and efficacySix months of hybrid closed loop in the real-world: An evaluation of children and young adults using the 670G systemReal world hybrid closed-loop discontinuation: Predictors and perceptions of youth discontinuing the 670G system in the first 6 monthsRandomized Controlled Trial of Mobile Closed-Loop ControlGlycemic Outcomes of Use of CLC Versus PLGS in Type 1 Diabetes: A Randomized Controlled Trial
P50
Q26997391-6DFE92EE-614A-4733-8C79-3D373743ADE3Q30354179-1C13B87A-F000-4C1E-BBB1-7AAD31E49C29Q36834244-A15FDE4E-412D-4E8A-A60E-9484B8D98115Q37062173-95FBD37D-2929-4103-A333-F671CC52946EQ37707026-BED7FF6B-D8AB-49AF-A458-6AD6F59E9BF9Q38811243-EFA61032-61B8-4DBC-8C31-C36B9978611CQ39159963-5C5D7EF9-47B1-4BAA-9B21-FF6A972A5D31Q39340823-1ADAC781-7F32-4573-9242-DB07AFB3C98FQ40335044-8AB1090B-E6B6-46D8-8E11-C6ECD304A284Q42208849-4D198E54-14EB-4E4E-98D7-38F0477A0A28Q43533271-C29A3CB7-0727-4ACE-B3AB-B8D903E63974Q44722129-F02BAA35-BC57-4910-81CF-8D0D1F50BD2CQ45066274-213012F6-83C2-48FC-AB96-BC03A39D36C9Q46215789-470C33F0-1F05-4ED8-8BA3-30283F239B44Q46726172-5E4AFFA7-FD28-43C3-B0AE-F0C8E911583DQ50042259-D8AF59B9-8A6D-45BA-A042-C0A9133B1038Q50047761-04D1A4C9-C236-46BE-A742-C7601D45B1A1Q51654262-E3DD4C5A-DC9B-4F04-9C4D-58E4029498B1Q52586603-075B5DD8-0861-4490-9766-88211169DC85Q53714062-574818E0-08BD-4249-9CAE-2E0BB1C259F4Q55361914-E24AA834-E1C3-4E3C-A330-5DE9085D6F61Q55397942-1F28A526-4CF2-4DF2-B076-B386F1EC0B89Q57136850-25914FE4-96CA-44E1-9886-64223BB08BAEQ61799686-F74B3201-87B2-4A3E-9FF2-D40202A2395DQ84291324-6DCFAE67-E540-4D50-B724-0E24E213178CQ88131429-1F045BB3-5900-47FF-BA47-F05BC927626DQ89148162-B5A136A8-AC95-46F8-951A-C92ECD4466BEQ90195319-7383F711-13C2-431D-925E-DF6A9EA3E5DEQ91975747-0AF05698-0951-4EED-BEF9-0A34FE98C4FEQ92305220-8335D106-05F7-49FC-B078-10A340810471Q92641736-4A152B52-D210-4A42-8AB3-E41CEB88D51FQ96022266-1CFE53CB-42EA-4834-889D-2C53B04F4DC8
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Gregory P Forlenza
@en
Gregory P Forlenza
@nl
type
label
Gregory P Forlenza
@en
Gregory P Forlenza
@nl
prefLabel
Gregory P Forlenza
@en
Gregory P Forlenza
@nl
P31
P496
0000-0003-3607-9788